NCT03270371

Brief Summary

This study examines whether medium-cut off dialysis results in improved blood purification of large middle molecules e.g. inflammatory molecules compared to hemodialysis (HD) treatments with conventional high-flux dialyzers.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable cardiovascular-diseases

Timeline
Completed

Started Sep 2017

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 25, 2017

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 1, 2017

Completed
Same day until next milestone

Study Start

First participant enrolled

September 1, 2017

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2018

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2019

Completed
Last Updated

September 1, 2017

Status Verified

August 1, 2017

Enrollment Period

1.1 years

First QC Date

August 25, 2017

Last Update Submit

August 29, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in inflammation

    change of inflammatory score (inflammatory score is derived from multiple biomarkers)

    240 days (cross-over design, multiple measurements)

Secondary Outcomes (2)

  • Change in calcification status

    240 days (cross-over design, multiple measurements)

  • change in calcification propensity

    240 days (cross-over design, multiple measurements)

Study Arms (2)

MCO Dialysis

EXPERIMENTAL

Theranova Dialyzer

Device: Medium cut off dialysis

Standard High Flux Dialysis

ACTIVE COMPARATOR

Standard High Flux Dialyzer

Device: Standard High Flux Dialyzer

Interventions

Hemodialysis

Also known as: Theranova Dialyzer
MCO Dialysis

Hemodialysis

Standard High Flux Dialysis

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • time since initiation of dialysis \> 3 months
  • age \> 18 years

You may not qualify if:

  • time since initiation of dialysis \< 3 months
  • age \< 18 years
  • ongoing acute or chronic infection/malignoma, because this will interfere with inflammatory baseline values
  • pregnancy
  • mental illness
  • lack of written and informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of nephrology, Klinikum rechts der Isar

München, Bavaria, 81675, Germany

RECRUITING

Related Publications (2)

  • Ronco C, La Manna G. Expanded Hemodialysis: A New Therapy for a New Class of Membranes. Contrib Nephrol. 2017;190:124-133. doi: 10.1159/000468959. Epub 2017 May 23.

    PMID: 28535525BACKGROUND
  • Zickler D, Schindler R, Willy K, Martus P, Pawlak M, Storr M, Hulko M, Boehler T, Glomb MA, Liehr K, Henning C, Templin M, Trojanowicz B, Ulrich C, Werner K, Fiedler R, Girndt M. Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis Patients-A Randomized Controlled Clinical Trial. PLoS One. 2017 Jan 13;12(1):e0169024. doi: 10.1371/journal.pone.0169024. eCollection 2017.

    PMID: 28085888BACKGROUND

MeSH Terms

Conditions

Cardiovascular DiseasesKidney Failure, Chronic

Condition Hierarchy (Ancestors)

Renal Insufficiency, ChronicRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Christoph Schmaderer, MD

    attending Department of Nephrology, Klinikum rechts der Isar

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Christoph Schmaderer, MD

CONTACT

Georg Lorenz, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
no masking
Purpose
TREATMENT
Intervention Model
CROSSOVER
Model Details: Medium cut off Dialyzer compared with standard of care High-Flux Dialyzer (Fx Cor Diax 60®). No others changes in our standard of care maintenance dialysis is planned, dialysis specific parameters such as blood flow will be kept unchanged during the study period).
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 25, 2017

First Posted

September 1, 2017

Study Start

September 1, 2017

Primary Completion

October 1, 2018

Study Completion

February 1, 2019

Last Updated

September 1, 2017

Record last verified: 2017-08

Data Sharing

IPD Sharing
Will not share

Locations